Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00214630 · ClinicalTrials.gov registry record · Phase 3
LUNAR IIIb Study Comparing Rosuvastatin and Atorvastatin in Subjects With Acute Coronary Syndromes
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 825
- Enrollment target
NCT00214630 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 825 participants.
The verdict
NCT00214630, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 825 participants
- Enrollment target
Study Summary
Comparison of rosuvastatin and atorvastatin in subjects with acute coronary syndromes
Interventions
- DRUG atorvastatin
- DRUG rosuvastatin calcium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 825 participants |
| Start Date | 2003-12 |
| Est. Completion | 2007-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00214630
The ClinicalTrials.gov registry entry for NCT00214630 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 825 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which atorvastatin is the first listed.
NCT00214630 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00214630 about?
NCT00214630 is a clinical study titled "LUNAR IIIb Study Comparing Rosuvastatin and Atorvastatin in Subjects With Acute Coronary Syndromes". Comparison of rosuvastatin and atorvastatin in subjects with acute coronary syndromes
What is the current status of trial NCT00214630?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 825 participants. The study started on 2003-12. Estimated completion is 2007-08.
What interventions are being tested in trial NCT00214630?
The interventions under investigation include: atorvastatin (DRUG), rosuvastatin calcium (DRUG).
Who is sponsoring clinical trial NCT00214630?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.